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The 2012 European Society of Cardiology (ESC)
ST-Elevation Myocardial Infarction (STEMI) guide-
line acknowledges that STEMI patients should
receive reperfusion therapy as soon as possible, and
that prehospital ﬁbrinolysis or ﬁeld-triage directly
to Primary Percutaneous Coronary Intervention
(PPCI) centres is the preferred reperfusion strategy.
1
However, when recommending ﬁbrinolytic therapy
(FT) within 30 min from First Medical Contact
(FMC), if PPCI cannot be performed ‘within
60 min of FMC in patients presenting early, with a
large amount of myocardium at risk’, the guidelines
imply that only 30 min extra may be expended to
perform PPCI instead of administering FT
(‘PCI-related delay’)( ﬁgure 1).
Throughout the years, successive guidelines have
mistakenly equated ‘PCI-related delay’ and ‘FMC to
PPCI’ (the total delay from FMC to PPCI) (ﬁgure 1).
This error persists in the recently updated ESC guide-
line.
1 Clariﬁcation of this distinction is of paramount
importance because of the suggested reduction in the
‘window of opportunity for PPCI’, a suggestion not
clearly supported by evidence, which has signiﬁcant
public health implications. In paragraph 3.5.2, the
ESC STEMI guideline references a registry analysis
from the National Registry of Myocardial Infarction
(NRMI),
2 concluding: ‘primary PCI (wire passage)
should be performed within 90 min after FMC in all
cases. In patients presenting early, with a large
amount of myocardium at risk, the delay should be
shorter (<60 min).’ The NRMI reference is also
listed in paragraph 3.4.1 in the ESC STEMI guideline
when recommending the acceptable ‘FMC-to-PCI’
delay of only 60 min in early incomers with anterior
infarction. However, this study describes ‘PCI-related
delay’, that is, the theoretical extra delay that may be
spent to perform PPCI over FT (ﬁgure 1). The
NRMI manuscript by Pinto et al. does not describe
‘FMC-to-PCI’ delay in the cohorts evaluated since
timing of Emergency Medical Service (EMS) evalu-
ation was imprecise. The only delay data available
were the interval ‘Door-to-balloon (D2B)’ delay,
which was 116 min when calculated as a weighted
mean (table 1). Given the fact that ‘FMC-to-PCI’ is
considerably longer than D2B delay among patients
transported by EMS (ﬁgure 1), the ‘FMC-to-PCI’
delay is likely to have been considerably longer than
120 min (table 1). Consequently, these data cannot
be applied recommendations regarding the optimal
time to ‘FMC to PCI’ or to support a recommenda-
tion ‘of a systems goal of FMC to PCI of 60 min.’ It
would appear that the 2012 STEMI guideline
authors,
1 when compiling the overwhelming amount
of scientiﬁc data, have either intended to use a differ-
ent reference or misinterpreted the ﬁndings from
Pinto et al’s original work.
2 We are not aware of sup-
portive data that would justify the current STEMI
guideline recommendations to consider ﬁbrinolysis
within 30 min of FMC when PPCI cannot be per-
formed within 60 min of FMC.
There have been several other studies addressing
the optimal ‘PCI-related delay’. The initial study by
Pinto and colleagues was limited by the fact that
optimal FT (ﬁbrin-speciﬁc drugs) was compared
with a less-than-optimal PPCI strategy (PPCI centres
performing only a mean of 20 PPCI procedures a
year).
2 A later analysis by Pinto and colleagues
found an acceptable ‘PCI-related delay’ of approxi-
mately 120 min without any excessive mortality in
PPCI-treated patients with anterior infarction or
short symptom duration, even at a PCI-related delay
of approximately 120 min.
3 While the magnitude of
survival difference between PPCI and FT decreased
as delay to PCI increased, at no point did mortality
for PPCI exceed that with FT. These ﬁndings are
concordant with the previous ﬁndings by Boersma
and colleagues that were based on individual data
from studies comparing FT with PPCI.
4 Swedish
registry data indicate a comparable outcome from
PPCI and FT, even with a PCI-related delay of
240 min, and observations from both the French
FAST-MI registry and the Vienna registry report
comparable outcomes for patients treated with FT
and PPCI with a PCI-related delay of 90 min.
5–7
The ESC STEMI guideline also relies upon analysis
of the Comparison of Angioplasty and Pre-hospital
Thrombolysis in Acute Myocardial Infarction
(CAPTIM) trial when recommending a
‘FMC-to-PPCI’ delay of 60 min.
8 This non-
prespeciﬁed subgroup analysis, based on 460
patients, claimed a lower mortality in patients rando-
mised to FT versus PPCI among subjects presenting
early. However, this ﬁnding did not reach statistical
signiﬁcance. A much larger meta-analysis including
individual data from 6763 patients demonstrated
superiority of PPCI over FT, in early as well as late
incomers.
4 This ﬁnding was also conﬁrmed in the
Swedish registry data.
5 It seems that the aforemen-
tioned subgroup analysis from CAPTIM was
weighted too heavily. Furthermore, ﬁndings from the
CAPTIM substudy offer little value in substantiating
a recommendation of ‘FMC to PPCI’ of <60 min,
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Point-Counterpointwhen the ‘FMC to PPCI’ delay must have been at least 100 min in
the trial. The time from symptom onset to randomisation was
108 min in the CAPTIM trial, and the time to PPCI was 190 min,
indicating that time from randomisation to PPCI was 82 min. The
response time (EMS call to arrival on scene) is typically about
10 min, and the ambulance physicians must have used at least
10 min on scene before randomisation. A conservative estimate,
t h u s ,i sa‘FMC to PPCI’ delay of at least 102 min in this study.
Consequently, neither the CAPTIM trial nor the NRMI analyses
support a ‘FMC to PPCI’ delay of <60 min.
Creation of a clinical guideline is an immense task, and we
commend the writing group for their efforts in creating a com-
prehensive and useful document summarising the available scien-
tiﬁc data informing management of STEMI patients. The
guidelines serve as a valuable resource, but the ﬂow charts and
suggestions may be more applicable for new STEMI networks in
regions without previously established systems of care. For well-
functioning STEMI networks, we believe that the best available
evidence supports a PCI-related delay <120 min. If existing
STEMI networks were to implement the shorter metrics intro-
duced in the current guidelines, there is a risk of FTadministra-
tion to patients where outcomes would be better with PPCI.
Finally, in regions with an ideal STEMI systems of care, with
prehospital diagnosis and ﬁeld-triage directly to large-volume
PPCI centres, FMC is variably deﬁned as time of EMS call
9 or
EMS arrival on scene. In regions that do not use prehospital diag-
nosis, FMC is simply the time of ambulance arrival at the hos-
pital. In self-presenters, FMC is also time of arrival at the hospital
(ﬁgure 1). It is necessary to standardise and differentiate recom-
mendations of ‘FMC to PPCI’ depending upon whether FMC is
EMS call or arrival at hospital because after all, the most import-
ant factor is rapid reperfusion with the most optimal strategy for
the patient. When comparing regions based on observed ‘FMC to
PPCI’ delays, it may erroneously seem that regions rightfully
focusing upon prehospital diagnosis are performing inferiorly
compared with regions that are not implementing prehospital
diagnosis, while the opposite is likely the case. In fact, if one were
to incorporate current ESC guideline recommendations of ‘FMC
to PPCI delay below 60 min’, in regions using prehospital diagno-
sis for ﬁeld-triage to PCI centres with rapid treatment times, FT
would be administered to more patients compared with regions
without prehospital diagnosis even though total ischaemic times
would have been shorter for the patients, or even more absurdly,
regions could eliminate prehospital diagnosis, increasing the
‘window of opportunity’ for PPCI.
We recommend that for future guidelines, professional
societies on both sides of the Atlantic acknowledge the current
confusion about the terminologies on treatment delays in STEMI
and uncertainties in utilising available data for information
regarding the proper treatment for various patient subsets, and
avoid recommendations that may have deleterious consequences.
It is uncertain whether a pharmacoinvasive strategy in the future
will qualify as an alternative reperfusion strategy. However, the
Strategic Reperfusion Early After Myocardial Infarction trial
found no mortality beneﬁt but an increased risk of stroke in
patients randomised to a pharmacoinvasive strategy compared to
patients randomised to a PPCI strategy.
10
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Figure 1 Various delays when
treating patients with ST-Elevation
Myocardial Infarction (STEMI) with
ﬁbrinolysis or primary percutaneous
coronary intervention (PPCI).
‘Healthcare system delay’ is the total
delay from emergency medical service
(EMS) call to PPCI. ‘PCI-related delay’
is the extra delay that one may use to
perform PPCI instead of administering
ﬁbrinolysis and still achieve a mortality
beneﬁt from PPCI. First Medical
Contact (either EMS call, EMS arrival
on scene, or arrival at hospital
according to regional STEMI system of
care).
Table 1 Delays to PPCI observed in the references used for recommendation of a First Medical Contact (FMC) to PPCI delay below 60 min in
the recent European Society of Cardiology 2012 STEMI-guidelines
References
Emergency medical service
call to arrival on scene
On scene
delay
Transport
delay
Door-to-balloon
delay (D2B)
Overall ‘FMC to
PCI’ delay
Pinto et al
2 NA NA NA 116 min* NA but >>>D2B delay!
Steg et al
1 NA NA NA NA NA but at least
102 min†
*In the Pinto et al reference D2B delays were presented for four groups varying from 91 to 179 min. The weighted mean D2B delay is presented here.
†None of the many papers from the CAPTIM trial have presented ‘FMC to PCI’ delay. Time to PPCI was 190 min and time to randomisation was 108 min. Adding 10 min for
emergency medical service response time and just 10 min on scene before randomisation, this would add up to a cumulative ‘FMC to PPCI’ delay of approximately 102 min.
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